Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Combined Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of MEDI4166 in Subjects With Type 2 Diabetes Mellitus (T2D)

NCT02524782 is registered in ClinicalTrials.gov with MedImmune LLC as lead sponsor.

NCT NCT02524782
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02524782 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Combined Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of MEDI4166 in Subjects With Type 2 Diabetes Mellitus (T2D)
Lead sponsor
MedImmune LLC
Phase
Phase 1
Overall status
Completed
Start date
October 7, 2015
Completion date
April 14, 2017
Enrollment
103 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes